Media Relations

Catch up on all H3 news and developments regarding research, ongoing trials and personnel.

In the News

Fierce Biotech

Chutes & Ladders

Eisai's cancer genomics drug discovery subsidiary, H3 Biomedicine, promoted Ping Zhu, Ph.D., to president and chief scientific officer, and Ross… Read More
FasterCures

Fixes in Financing

High-risk, long-term investments are needed to turn medical innovations into lifesaving therapies. At FasterCures, we examine and highlight innovative funding mechanisms… Read More
European Business Review

Personal Medicine

Biomarker research is fundamental to the delivery of targeted therapeutics. An industry shift towards a more collaborative approach to patient-derived… Read More

Company
Information

H3 Biomedicine was founded in 2011 as a research and development engine focused on advancing drugs from bench to bedside.

For all media interested in speaking to members of H3 Biomedicine’s team, or receiving further information about the company or pipeline, please contact us.

Want to learn more about H3 from our team?

Inquire